Spironolactone therapy is associated with reduced ventricular tachycardia rate in patients with cardiomyopathy

PACE - Pacing and Clinical Electrophysiology

Volumn 34, Issue 3, 2011, Pages 309-314

  Dimas, Vassilis ^a   Ayers, Colby ^b   Daniels, James ^a   Joglar, Jose A ^a   Hill, Joseph A ^a,b   Naseem, R Haris ^a,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

antifibrotic therapies; cardiomyopathy; electrophysiology; spironolactone; ventricular tachycardia

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SPIRONOLACTONE;

AGED; ARTICLE; CARDIOMYOPATHY; FEMALE; HEART FAILURE; HEART VENTRICLE TACHYCARDIA; HUMAN; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY;

AGED; CARDIOMYOPATHIES; COMORBIDITY; DIURETICS; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; SPIRONOLACTONE; TACHYCARDIA, VENTRICULAR; TEXAS; TREATMENT OUTCOME;

EID: 79952466122     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2010.02888.x     Document Type: Article

References (29)

1. Hill JA, Olson EN,. Cardiac plasticity. N Engl J Med 2008; 358: 1370-1380.
2. McLenachan JM, Henderson E, Morris KI, Dargie HJ,. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Engl J Med 1987; 317: 787-792. (Pubitemid 17133358)
3. Manabe I, Shindo T, Nagai R,. Gene expression in fibroblasts and fibrosis: Involvement in cardiac hypertrophy. Circ Res 2002; 91: 1103-1113. (Pubitemid 36076358)
4. Weber KT,. Fibrosis in hypertensive heart disease: Focus on cardiac fibroblasts. J Hypertens 2004; 22: 47-50. (Pubitemid 38293529)
5. Zeppenfeld K, Stevenson WG,. Ablation of ventricular tachycardia in patients with structural heart disease. Pacing Clin Electrophysiol 2008; 31: 358-374. (Pubitemid 351337530)
6. Spach MS, Boineau JP,. Microfibrosis produces electrical load variations due to loss of side-to-side cell connections: A major mechanism of structural heart disease arrhythmias. Pacing Clin Electrophysiol 1997; 20: 397-413.
7. Miragoli M, Gaudesius G, Rohr S,. Electrotonic modulation of cardiac impulse conduction by myofibroblasts. Circ Res 2006; 98: 801-810.
8. Miragoli M, Salvarani N, Rohr S,. Myofibroblasts induce ectopic activity in cardiac tissue. Circ Res 2007; 101: 755-758. (Pubitemid 350287189)
9. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, Chandraker A, et al,. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007; 13: 952-961. (Pubitemid 47222040)
10. Spinale FG,. Myocardial matrix remodeling and the matrix metalloproteinases: Influence on cardiac form and function. Physiol Rev 2007; 87: 1285-1342. (Pubitemid 350041472)
11. Everett THt, Olgin JE,. Atrial fibrosis and the mechanisms of atrial fibrillation. Heart Rhythm 2007; 4: S24-S27.
12. Lea WB, Kwak ES, Luther JM, Fowler SM, Wang Z, Ma J, Fogo AB, et al,. Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int 2009; 75: 936-944.
13. Brilla CG, Matsubara LS, Weber KT,. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993; 25: 563-575. (Pubitemid 23208145)
14. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, et al,. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717. (Pubitemid 29407370)
15. Zannad F, Alla F, Dousset B, Perez A, Pitt B,. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000; 102: 2700-2706.
16. Van Den Borne SW, Isobe S, Zandbergen HR, Li P, Petrov A, Wong ND, Fujimoto S, et al,. Molecular imaging for efficacy of pharmacologic intervention in myocardial remodeling. JACC Cardiovasc Imaging 2009; 2: 187-198.
17. Massare J, Berry JM, Luo X, Rob F, Johnstone JL, Shelton JM, Bassel-Duby R, et al,. Diminished cardiac fibrosis in heart failure is associated with altered ventricular arrhythmia phenotype. J Cardiovasc Electrophysiol 2010 (in press).
18. Sadoul N, Mletzko R, Anselme F, Bowes R, Schöls W, Kouakam C, Casteigneau G, et al,. Incidence and clinical relevance of slow ventricular tachycardia in implantable cardioverter-defibrillator recipients: An international multicenter prospective study. Circulation 2005; 112: 946-953. (Pubitemid 41170261)
19. Wathen MS, DeGroot PJ, Sweeney MO, Stark AJ, Otterness MF, Adkisson WO, Canby RC, et al,. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results. Circulation 2004; 110: 2591-2596. (Pubitemid 39453007)
20. Wathen MS, Sweeney MO, DeGroot PJ, Stark AJ, Koehler JL, Chisner MB, Machado C, et al,. Shock reduction using antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with coronary artery disease. Circulation 2001; 104: 796-801. (Pubitemid 32762678)
21. Sweeney MO, Sherfesee L, DeGroot PJ, Wathen MS, Wilkoff BL,. Differences in effects of electrical therapy type for ventricular arrhythmias on mortality in implantable cardioverter-defibrillator patients. Heart Rhythm 2010; 7: 353-360.
22. Varnava AM, Elliott PM, Mahon N, Davies MJ, McKenna WJ,. Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. Am J Cardiol 2001; 88: 275-279. (Pubitemid 32721955)
23. Laflamme MA, Murry CE,. Regenerating the heart. Nat Biotechnol 2005; 23: 845-856. (Pubitemid 43093128)
24. Duffy HS,. Cardiac connections-The antiarrhythmic solution? N Engl J Med 2008; 358: 1397-1398.
25. Roell W, Lewalter T, Sasse P, Tallini YN, Choi BR, Breitbach M, Doran R, et al,. Engraftment of connexin 43-expressing cells prevents post-infarct arrhythmia. Nature 2007; 450: 819-824. (Pubitemid 350237591)
26. Brown RD, Ambler SK, Mitchell MD, Long CS,. The cardiac fibroblast: Therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol 2005; 45: 657-687. (Pubitemid 40261821)
27. Iraqi W, Rossignol P, Angioi M, Fay R, Nuée J, Ketelslegers JM, Vincent J, et al,. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: Insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation 2009; 119: 2471-2479.
28. Ten Tusscher KH, Panfilov AV,. Influence of diffuse fibrosis on wave propagation in human ventricular tissue. Europace 2007; 9 (Suppl 6): vi38-vi45.
29. Schaumann A, von zur Muhlen F, Herse B, Gonska BD, Kreuzer H,. Empirical versus tested antitachycardia pacing in implantable cardioverter defibrillators: a prospective study including 200 patients. Circulation 1998; 97: 66-74. (Pubitemid 28036156)